Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Apr 2026

Moretti Nayara Rozalem, Kamitani Hideki Zimermann, de Souza Wagner Pedro Henrique, Matheus Gustavo Tadeu Freitas Uchôa, Talah Barbara Antonia Dups, Tanimoto Larissa Emi, de Oliveira Barretto Isabella Caroline, de Moraes Francisco Cezar Aquino

Abstract excerpt

BACKGROUND: Endometrial cancer (EC) is the sixth most common female cancer and may rank fourth in cancer mortality by 2040. TP53 mutations and aberrant p53 expression are associated to aggressive tumor subtypes and poor prognosis, reducing overall survival (OS), disease-free survival, recurrence rates (RcR) and Mortality Risk (MR). The prognostic impact of TP53 mutations in EC remains unclear. METHODS: A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to TP53 gene

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41107655
DOI: 10.1007/s12094-025-04076-9

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.PMID 41107655Read ↗

Clinical Profile and Survival Outcome of Endometrial Cancer with p53 MutationSemantic proximity Read ↗

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial CarcinomaSemantic proximity Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer.Semantic proximity Read ↗

p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.Semantic proximity Read ↗

Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer.Semantic proximity Read ↗

The mutational landscape of endometrial cancer.Semantic proximity Read ↗

Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study.Semantic proximity Read ↗

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial.Semantic proximity Read ↗

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.Semantic proximity Read ↗

TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.Semantic proximity Read ↗

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.